HMR 3339, a novel selective estrogen receptor modulator, reduces total cholesterol, low-density lipoprotein cholesterol, and homocysteine in healthy postmenopausal women

被引:14
作者
Vogelvang, TE
Mijatovic, V
Kenemans, P
Teerlink, T
van der Mooren, MJ
机构
[1] Vrije Univ Amsterdam, Med Ctr, Dept Obstet & Gynecol, Project Aging Women, NL-1007 MB Amsterdam, Netherlands
[2] Vrije Univ Amsterdam, Med Ctr, ICaR, NL-1007 MB Amsterdam, Netherlands
关键词
HMR; 3339; raloxifene; menopause; lipids; lipoprotein(a); homocysteine; endothelin-1;
D O I
10.1016/j.fertnstert.2004.05.093
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: To investigate the short-term effects of HMR 3339 in comparison with raloxifene and placebo on cardiovascular risk factors. Design: A multicenter, randomized, placebo-controlled, double-blind, dose-ranging study. Setting: Gynecologic outpatient department. Patient(s): One hundred eighteen healthy nonhysterectomized postmenopausal women. Intervention(s): Participants received daily placebo (n = 22), 2.5 mg of HMR 3339 (n = 25), 10 mg of HMR 3339 (n = 24), 50 mg of HMR 3339 (n = 24), or 60 mg of raloxifene (n = 23) for 12 weeks followed by a 2-week washout period. Main Outcome Measure(s): Blood concentrations of lipids measured at baseline, and after 2, 4, 8, 12, and 14 weeks, and of lipoprotein(a), homocysteine, and endothelin-1 measured at baseline, and after 4 and 12 weeks. Result(s): After 12 weeks of treatment with HMR 3339, compared with placebo, serum total cholesterol was reduced (10 mg of HMR 3339: -9.7%; 50 mg of HMR 3339: -15.2%), low-density lipoprotein (LDL)-cholesterol (10 mg of HMR 3339: -10.8%; 50 mg of HMR 3339: -24.2%) and plasma homocysteine concentrations (2.5 mg of HMR 3339: -3.9%; 10 mg of HMR 3339: -10.8%; 50 mg of HMR 3339: -13.8%), suggesting a dose-dependent effect of HMR 3339. These effects were already apparent after 2 weeks of treatment for total cholesterol and LDL-cholesterol, and after 4 weeks of treatment for homocysteine. After 12 weeks, raloxifene, compared with placebo, significantly decreased total cholesterol (-10.5%), LDL-cholesterol (-15.0%), and triglycerides (-16.9%), but not homocysteine. High-density lipoprotein-cholesterol, lipoprotein(a), and endothelin-1 showed no significant changes in any of the active treatment groups. Conclusion(s): HMR 3339 reduces total cholesterol, LDL-cholesterol, and homocysteine concentrations in postmenopausal women. (C) 2004 by American Society for Reproductive Medicine.
引用
收藏
页码:1540 / 1549
页数:10
相关论文
共 28 条
[1]   Raloxifene and cardiovascular events in osteoporotic postmenopausal women - Four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial [J].
Barrett-Connor, E ;
Grady, D ;
Sashegyi, A ;
Anderson, PW ;
Cox, DA ;
Hoszowski, K ;
Rautaharju, P ;
Harper, KD .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 287 (07) :847-857
[2]   Long-term effects of oral and transdermal hormone replacement therapy on plasma homocysteine levels [J].
Chiantera, V ;
Sarti, CD ;
Fornaro, F ;
Farzati, A ;
De Franciscis, P ;
Sepe, E ;
Borrelli, AL ;
Colacurci, N .
MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2003, 10 (04) :286-291
[3]   Effects of estrogen-progestin and raloxifene therapy on nitric oxide, prostacyclin and endothelin-1 synthesis [J].
Christodoulakos, G ;
Panoulis, C ;
Kouskouni, E ;
Chondros, C ;
Dendrinos, S ;
Creatsas, G .
GYNECOLOGICAL ENDOCRINOLOGY, 2002, 16 (01) :9-17
[4]   Randomized control study of the effects of raloxifene on serum lipids and homocysteine in older women [J].
De Leo, V ;
la Marca, A ;
Morgante, G ;
Lanzetta, D ;
Setacci, C ;
Petraglia, F .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2001, 184 (03) :350-353
[5]   Both raloxifene and estrogen reduce major cardiovascular risk factors in healthy postmenopausal women - A 2-year, placebo-controlled study [J].
de Valk-de Roo, GW ;
Stehouwer, CDA ;
Meijer, P ;
Mijatovic, V ;
Kluft, C ;
Kenemans, P ;
Cohen, F ;
Watts, S ;
Netelenbos, C .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1999, 19 (12) :2993-3000
[6]  
FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499
[7]   Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein (a) concentrations: analysis of studies published from 1974-2000 [J].
Godsland, IF .
FERTILITY AND STERILITY, 2001, 75 (05) :898-915
[8]   Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women [J].
Hulley, S ;
Grady, D ;
Bush, T ;
Furberg, C ;
Herrington, D ;
Riggs, B ;
Vittinghoff, E .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (07) :605-613
[9]   RISK-FACTORS THAT ATTENUATE THE FEMALE CORONARY-DISEASE ADVANTAGE [J].
KANNEL, WB ;
WILSON, PWF .
ARCHIVES OF INTERNAL MEDICINE, 1995, 155 (01) :57-61
[10]  
Knopp RH, 2002, AM J CARDIOL, V89, p28E